---
title: "Entyvio (vedolizumab) in ulcerative colitis: Safety questions"
description: "Safety questions on Entyvio (vedolizumab) in ulcerative colitis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects. Questions: What side effects occurred with Entyvio vs Humira in VARSITY? What are the most common side effects of Entyvio? How common are injection site reactions with the Entyvio Pen? What are the long-term side effects of Entyvio? 4 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/safety"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Entyvio (vedolizumab) in ulcerative colitis: Safety questions

Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.  
Prescribing information: [Entyvio](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1)

Safety questions that apply to every indication of Entyvio are on [Entyvio (vedolizumab), all indications: Safety](https://www.evicenter.com/medical-information/entyvio/safety).

## Side effects

<a id="entyvio-varsity-side-effects"></a>

### What side effects occurred with Entyvio vs Humira in VARSITY?

Applies to: Moderately to severely active ulcerative colitis in adults, intravenous induction and maintenance

> “Safety was evaluated in 383 patients”

Source: [ENTYVIO: Safety Profile for ENTYVIO® (vedolizumab), captured 2026-11-13](https://www.entyviohcp.com/safety-profile#:~:text=Safety%20was%20evaluated%20in%20383%20patients)

> “Study was not designed to assess safety differences”

Source: [ENTYVIO: Safety Profile for ENTYVIO® (vedolizumab), captured 2026-11-13](https://www.entyviohcp.com/safety-profile#:~:text=Study%20was%20not%20designed%20to%20assess%20safety%20differences)

> “The most frequent AEs for Humira<sup>®</sup> and ENTYVIO were as follows: ≥1 TEAE, 35.8% and 32.9%; UC, 16.3% and 11.5%; nasopharyngitis, 7.8% and 7.0%; headache, 5.4% and 7.0%; anemia, 6.7% and 5.2%; abdominal pain, 5.2% and 4.7%; upper respiratory tract infection, 4.4% and 5.2%<sup>†</sup>”

Source: [ENTYVIO: Safety Profile for ENTYVIO® (vedolizumab), captured 2026-11-13](https://www.entyviohcp.com/safety-profile#:~:text=The%20most%20frequent%20AEs%20for,respiratory%20tract%20infection%2C%204.4%25%20and)

> “<sup>†</sup>Adverse events that occurred during the trial period. Trial period was the time from the first dose of a trial drug and up to 126 days after the last dose. Adverse events were classified according to the Medical Dictionary for Regulatory Activities System Organ Class categorization and preferred terms (version 21.0). The safety population was defined as all patients who received at least 1 dose of the study drug.”

Source: [ENTYVIO: Safety Profile for ENTYVIO® (vedolizumab), captured 2026-11-13](https://www.entyviohcp.com/safety-profile#:~:text=events%20that%20occurred%20during%20the,dose%20of%20the%20study%20drug.)

Note: In each pair of percentages the Humira value is first and the ENTYVIO value second, as the sentence states. The 383 patients match the ENTYVIO arm of VARSITY; the efficacy page lists 386 patients in the Humira arm.

<a id="entyvio-common-side-effects"></a>

### What are the most common side effects of Entyvio?

> “Adverse reactions were reported in 52% of patients treated with intravenous ENTYVIO and 
> 45% of patients treated with placebo (UC Trials I and II: 49% with ENTYVIO and 37% with 
> placebo; CD Trials I and III: 55% with ENTYVIO and 47% with placebo). Serious adverse 
> reactions were reported in 7% of patients treated with intravenous ENTYVIO compared 
> to 4% of patients treated with placebo (UC Trials I and II: 8% with ENTYVIO and 7% with 
> placebo; CD Trials I and III: 12% with ENTYVIO and 9% with placebo).”

Source: [ENTYVIO: Prescribing information, page 3, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=3)

> “The most common adverse reactions (reported by ≥3% of patients treated with intravenous 
> ENTYVIO in the UC Trials I and II and CD Trials I and III combined group and ≥1% higher 
> than in combined placebo group) were nasopharyngitis, headache, arthralgia, nausea, 
> pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, 
> rash, pruritus, sinusitis, oropharyngeal pain, and pain in extremities (Table 2).”

Source: [ENTYVIO: Prescribing information, page 3, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=3)

> “Table 2. Adverse Reactions in ≥3% of Intravenous ENTYVIO-Treated Adult Patients and 
> ≥1% Higher than in Placebo (UC Trials I and II* and CD Trials I and III*)
> Adverse Reaction
> ENTYVIO IV†
> (N=1434)
> Placebo‡
> (N=297)
> Nasopharyngitis
> 13%
> 7%
> Headache
> 12%
> 11%
> Arthralgia
> 12%
> 10%
> Nausea
> 9%
> 8%
> Pyrexia
> 9%
> 7%
> Upper respiratory tract infection
> 7%
> 6%
> Adverse Reaction
> ENTYVIO IV†
> (N=1434)
> Placebo‡
> (N=297)
> Fatigue
> 6%
> 3%
> Cough
> 5%
> 3%
> Bronchitis
> 4%
> 3%
> Influenza
> 4%
> 2%
> Back pain
> 4%
> 3%
> Rash
> 3%
> 2%
> Pruritus
> 3%
> 1%
> Sinusitis
> 3%
> 1%
> Oropharyngeal pain
> 3%
> 1%
> Pain in extremities
> 3%
> 1%
> * Data from patients receiving open-label intravenous ENTYVIO treatment at Weeks 0 and 2 (prior to entry into
> UC Trial II and CD Trial III) and from Weeks 6 to 52 (non-responders at Week 6 of UC Trial I and CD 
> Trial I) are included.
> †  Patients who received ENTYVIO for up to 52 weeks.
> ‡  Patients who received placebo for up to 52 weeks.”

Source: [ENTYVIO: Prescribing information, page 3, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=3)

Note: Table 2 pools the ulcerative colitis trials (UC Trials I and II) with the Crohn's disease trials (CD Trials I and III); the label gives ulcerative colitis rates separately only for any and serious adverse reactions, in the first passage. Table 2 columns are ENTYVIO IV (N=1434) and placebo (N=297).

<a id="entyvio-injection-site-reactions"></a>

### How common are injection site reactions with the Entyvio Pen?

Applies to: Moderately to severely active ulcerative colitis in adults, subcutaneous maintenance after two intravenous induction doses

> “The safety profile for up to 52 weeks of total treatment was similar between patients who 
> were switched to ENTYVIO as a subcutaneous injection in SC UC and SC CD clinical trials and 
> patients in UC and CD clinical trials who received ENTYVIO as an intravenous infusion (Table 
> 2) except for injection site reactions, which were reported with subcutaneous ENTYVIO. 
> Injection site reactions with subcutaneous ENTYVIO were reported in 10% (11/106) of 
> patients in SC UC Trial, including injection site erythema, rash, pruritus, swelling, bruising, 
> and hematoma.”

Source: [ENTYVIO: Prescribing information, page 4, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=4)

> “ISRs did not lead to discontinuation of, or changes to, the study medication dose<sup>5</sup>”

Source: [ENTYVIO: Safety Profile for ENTYVIO® (vedolizumab), captured 2026-11-13](https://www.entyviohcp.com/safety-profile#:~:text=ISRs%20did%20not%20lead%20to,changes%20to%2C%20the%20study%20medication)

<a id="entyvio-long-term-side-effects"></a>

### What are the long-term side effects of Entyvio?

> “GEMINI Long-term Safety Study was a phase 3, single-arm, open-label, multinational study”

Source: [ENTYVIO: Safety Profile for ENTYVIO® (vedolizumab), captured 2026-11-13](https://www.entyviohcp.com/safety-profile#:~:text=GEMINI%20Long%2Dterm%20Safety%20Study%20was%20a%20phase%203%2C%20single%2Darm%2C%20open%2Dlabel%2C%20multinational%20study)

> “The study evaluated 2243 patients with ulcerative colitis or Crohn’s disease who received ENTYVIO for a median of 42.4 months”

Source: [ENTYVIO: Safety Profile for ENTYVIO® (vedolizumab), captured 2026-11-13](https://www.entyviohcp.com/safety-profile#:~:text=The%20study%20evaluated%202243%20patients,a%20median%20of%2042.4%20months)

> “No new signals of<sup>2,3</sup>
> Infections
> Infusion-related reactions
> Malignancies
> Hepatic injury”

Source: [ENTYVIO: Safety Profile for ENTYVIO® (vedolizumab), captured 2026-11-13](https://www.entyviohcp.com/safety-profile#:~:text=No%20new%20signals,Hepatic%20injury)

> “Over 48 months, there was no increase in the 
> rate of serious infections.”

Source: [ENTYVIO: Prescribing information, page 3, captured 2026-11-13](https://content.takeda.com/?contenttype=PI&product=ENTY&language=ENG&country=USA&documentnumber=1#page=3)

Note: The long-term safety study had no comparator arm and enrolled patients with ulcerative colitis or Crohn's disease; the page presents its exposure-adjusted incidence rates in a figure whose values are not in the page text. The label sentence on serious infections follows the pooled ulcerative colitis and Crohn's disease trial data and does not name the source of the 48-month data.

## Related pages
- [Medical information: Entyvio (vedolizumab): Ulcerative colitis](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis)
- [Indication](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/clinical-trials)
- [Dosing and administration](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/entyvio--ulcerative-colitis/guidelines)
